Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
| Property | Value | Notes |
|---|---|---|
| Analytical method | Reversed-phase HPLC | Purity determination, typically 214 nm |
| Mass confirmation | ESI or MALDI mass spectrometry | Compared with mass near 390 Da |
| Common synonyms | Epitalon, epithalon, AEDG | Naming differs between suppliers |
| Storage temperature | −20 °C or lower | Lyophilised powder, kept desiccated |
| Solution stability | Limited in neutral aqueous buffer | Aspartimide and hydrolysis pathways |
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
The first true chromatography is usually attributed to the Russian-Italian botanist Mikhail Tsvet. Tsvet applied his observations with filter paper extraction to the new methods of column fractionation that had been developed in the 1890s for separating the components of petroleum. He used a liquid-adsorption column containing calcium carbonate to separate yellow, orange, and green plant pigments (what are known today as xanthophylls, carotenes, and chlorophylls, respectively). The method was described on December 30, 1901, at the 11th Congress of Naturalists and Doctors (XI съезд естествоиспытателей и врачей) in Saint Petersburg. The first printed description was in 1903, in the Proceedings of the Warsaw Society of Naturalists, section of biology. He first used the term chromatography in print in 1906 in his two papers about chlorophyll in the German botanical journal, Berichte der Deutschen Botanischen Gesellschaft. In 1907 he demonstrated his chromatograph for the German Botanical Society. Mikhail's surname "Цвет" means "color" in Russian, so there is the possibility that his naming the procedure chromatography (literally "color writing") was a way that he could make sure that he, a commoner in Tsarist Russia, could be immortalized. In a 1903 lecture (published in 1905), Tsvet also described using filter paper to approximate the properties of living plant fibers in his experiments on plant pigments—a precursor to paper chromatography.
In 1943, Glaxo was responsible for 2,570 million of the 3,500 million Oxford units produced in the UK. Glaxo opened a third factory at Watford in February 1944 and a fourth at Stratford, London, in January 1945. The company was responsible for 80 per cent of the UK's output up to June 1944. In 1944 the Ministry of Supply arranged for the Commercial Solvents Company to install the first deep submergence plant at Speke, and it asked Glaxo to build one too. This new Glaxo plant opened at Barnard Castle in January 1946 and produced more penicillin over the next nine months than its surface plants had produced in all of 1945. The surface plants were all closed in 1946. Penicillin production in the UK increased from 25 million units per week in March 1943 to 30 billion per week in 1946.
=== 2010 census === As of the census of 2010, there were 15,792 people, 6,433 households, and 4,049 families living in the city. The population density was 1,014.9 inhabitants per square mile (391.9/km2). There were 7,057 housing units at an average density of 453.5 per square mile (175.1/km2). The racial makeup of the city was 96.1% White, 0.5% African American, 0.2% Native American, 0.6% Asian, 1.1% from other races, and 1.5% from two or more races. Hispanic or Latino of any race were 3.1% of the population. There were 6,433 households, of which 32.6% had children under the age of 18 living with them, 46.0% were married couples living together, 11.8% had a female householder with no husband present, 5.2% had a male householder with no wife present, and 37.1% were non-families. 30.9% of all households were made up of individuals, and 11.8% had someone living alone who was 65 years of age or older. The average household size was 2.38 and the average family size was 2.97. The median age in the city was 37.5 years. 24.5% of residents were under the age of 18; 8.5% were between the ages of 18 and 24; 26.8% were from 25 to 44; 25.6% were from 45 to 64; and 14.7% were 65 years of age or older. The gender makeup of the city was 48.0% male and 52.0% female.
The lamina propria is a thin layer of connective tissue that forms part of the moist linings known as mucous membranes or mucosae, which line various tubes in the body, such as the respiratory tract, the gastrointestinal tract, and the urogenital tract. The lamina propria is a thin layer of loose (areolar) connective tissue, which lies beneath the epithelium, and together with the epithelium and basement membrane constitutes the mucosa. As its Latin name indicates, it is a characteristic component of the mucosa, or the mucosa's "own special layer." Thus, the term mucosa or mucous membrane refers to the combination of the epithelium and the lamina propria. The connective tissue of the lamina propria is loose and rich in cells. The cells of the lamina propria are variable and can include fibroblasts, lymphocytes, plasma cells, macrophages, eosinophilic leukocytes, and mast cells. It provides support and nutrition to the epithelium, as well as the means to bind to the underlying tissue. Irregularities in the connective tissue surface, such as papillae found in the tongue, increase the area of contact of the lamina propria and the epithelium.
Their mass-to-charge ratio is proportional to their time of flight (TOF) in the drift tube and can be calculated accordingly. Coupling ESI with capillary LC can separate peptides from protein digests, while obtaining their molecular masses at the same time. Capillary electrophoresis coupled with ESI-MS is another technique; however, it works best when analyzing small amounts of proteins.
Sources: en.wikipedia.org
=== Post-production === The filmmakers experimented with the visuals of Mega-City One, including the design and positioning of the city's tower blocks, to create the impression that the city had risen out of the remains of another. They found that replicating the comic visuals of blocks close together made the blocks appear small. Instead, they allowed more space between the buildings to emphasise the larger buildings and allow for the presence of roads and cars to allow for extrapolation outside of the picture. Outcrops and appendages were added to break up the buildings' straight lines. On 7 October 2011, the Los Angeles Times reported that Travis was prohibited from participating in the editing process following creative disagreements between producers and executives. Garland took over the editing process; his contribution was considered significant enough for him to seek a co-director credit—a situation considered unusual as Garland had never directed a film before and had not been in charge of any filming. The disagreement concerned a disapproval over the footage that Travis was providing. Although Travis was removed from the editing process, he was monitoring the progress of the film. On 10 October, Travis and Garland released a joint statement saying that they had agreed on an "unorthodox collaboration" before production began, that Travis was still involved in the film and that Garland was not seeking a co-director credit. In March 2018, Urban said that he believed Dredd should be considered Garland's directorial debut.
== Further reading == Webster, Gregory K.; Kott, L; Maloney, T; et al. (2005). "JALA Tutorial: Considerations When Implementing Automated Methods into GxP Laboratories". Journal of the Association for Laboratory Automation. 10 (3). Elsevier: 182–191. doi:10.1016/j.jala.2005.03.003.
Unlike standard SPPS (which is limited to 50 amino acid residue) NCL allows the construction of large glycopeptides. However the strategy is limited by the fact that it requires a cysteine residue at N-terminus, an amino acid residue that is rare in nature. However this problem has partly been address by the selective desulfurization of the cysteine residue to an alanine.
=== No development reported === ADX-71149 (JNJ-1813; JNJ-40411813; JNJ-mGluR2-PAM) – metabotropic glutamate mGlu2 receptor positive allosteric modulator [5] Tebideutorexant (JNJ-61393215; JNJ-3215) – orexin OX1 receptor antagonist [6]
The earliest form of curing is drying, which has been in use since ancient times, the earliest known practice dates back to 12,000 B.C. by inhabitants of the modern Asian and Middle Eastern regions. Water is traditionally removed through evaporation by using methods such as air drying, sun drying, smoking or wind drying, although today electric food dehydrators can be used to speed the drying process and ensure more consistent results.
Sources: en.wikipedia.org
=== Center of Excellence for Transgender Health (UCSF) === The Center of Excellence for Transgender Health at the University of California, San Francisco was established in 2009, dedicated to improving health equity for trans and gender nonconforming communities. The Center of Excellence for Transgender Health is a national advisory board composed of transgender leaders from across the United States, bringing expertise in the research of transgender health. Guidelines for Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People contains guidelines developed by The Center of Excellence for Transgender Health that are widely used clinical guidelines for transgender healthcare.
=== Australia === Australia has documented 10 cases of healthcare-acquired CJD (iatrogenic or ICJD). Five of the deaths resulted after the patients, who were in treatment either for infertility or short stature, were treated using contaminated pituitary extract hormone but no new cases have been noted since 1991. The other five deaths occurred due to dura mater grafting procedures that were performed during brain surgery, in which the covering of the brain is repaired. There have been no other ICJD deaths documented in Australia due to transmission during healthcare procedures.
=== Investigation === If C-4 is marked with a taggant, such as DMNB, it can be detected with an explosive vapor detector before it has been detonated. A variety of methods for explosive residue analysis may be used to identify C-4. These include optical microscope examination and scanning electron microscopy for unreacted explosive, chemical spot tests, thin-layer chromatography, X-ray crystallography, and infrared spectroscopy for products of the explosive chemical reaction. Small particles of C-4 may be easily identified by mixing with thymol crystals and a few drops of sulfuric acid. The mixture will become rose colored upon addition of a small quantity of ethyl alcohol. RDX has a high birefringence, and the other components commonly found in C-4 are generally isotropic; this makes it possible for forensic science teams to detect trace residue on fingertips of individuals who may have recently been in contact with the compound. However, positive results are highly variable and the mass of RDX can range between 1.7 and 130 ng, each analysis must be individually handled using magnifying equipment. The cross polarized light images obtained from microscopic analysis of the fingerprint are analyzed with gray-scale thresholding to improve contrast for the particles. The contrast is then inverted in order to show dark RDX particles against a light background. Relative numbers and positions of RDX particles have been measured from a series of 50 fingerprints left after a single contact impression. Military and commercial C-4 are blended with different oils.
The two substrates of this enzyme are (S)-3-(imidazol-5-yl)lactic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are imidazole-4-pyruvic acid, reduced NADH, and a proton. The enzyme can use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-3-(imidazol-5-yl)lactate:NAD(P)+ oxidoreductase. This enzyme is also called imidazol-5-yl lactate dehydrogenase.
== Discovery == Catch bonds were first proposed in 1988 in the Proceedings of the Royal Society by M. Dembo et al. while at Los Alamos National Laboratory. While developing molecular model to study the critical tension required to detach a membrane bound to a surface through adhesion molecules, it was found that it is theoretically possible for bond dissociation to be increased by force, decreased by force, and independent of force. The terms "slip bond", "catch bond", and "ideal bond" were coined by Dembo to describe these three types of bond behaviors. Slip bonds represent the ordinary behavior originally modeled by G. Bell, Dembo's former postdoctoral mentor at Los Alamos National Laboratory in 1978. Slip bonds were supported by flow chamber experiments where forces are applied on molecular bonds linking cells to chamber floor under shear flow. By comparison, no decisive evidence of catch bonds was found until 2003. This is due to experimental conditions that were unfavorable for detecting catch bonds, as well as the counterintuitive nature of the bonds themselves. For example, most early experiments were conducted in 96 well plates, an environment that does not provide any flow. Some experiments failed to produce shear stress that is now known to be critical to lengthen the lifetimes of catch bonds, while other experiments conducted under flow conditions too weak or too strong for optimal shear-induced strengthening of these bonds.
Sources: en.wikipedia.org
The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.
Neutral and slightly basic aqueous conditions promote aspartimide formation at the aspartate-glycine step, often followed by deamidation. Elevated temperature and repeated freeze-thaw cycles accelerate the loss. Acidic solutions and dry lyophilised powder are comparatively stable over short periods.
No monograph exists in the United States Pharmacopeia or the European Pharmacopoeia, and no widely distributed certified reference standard is available. Purity and identity therefore rest on supplier methods that are not harmonised. This absence is the main reason reported purities are difficult to compare between sources.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.